摘要
目的:介绍一种快速定量检测HBV DNA的方法及临床初步应用。方法:对40例乙型肝炎病毒表面抗原阳性的慢性乙型肝炎患者共79份血清标本,采用Digene第二代杂交捕获试验(Hybrid Capture Ⅱ,HC Ⅱ,v2.0)定量检测HBVDNA,并与分枝链DNA信号扩增试验(bDNA,v1.0)作比较。结果:79份HBsAg阳性血清中,HC Ⅱ检出HBV DNA 57份(72.2％),bDNA法为45份(57％),HC Ⅱ敏感性略高于bDNA法;2种方法定量检测HBV DNA的符合率为85.9％,相关性良好(r=0.95);19例抗病毒治疗乙肝患者,治疗后平均HBV DNA载量下降2(Log10)数量级,6例发生e抗原血清转换的患者平均HBV DNA载量下降3(Log10)数量级以上,且HBV DNA阴转早于e抗原血清转换。结论:HC Ⅱ比bDNA更为简便、经济、快速,可用于临床HBV DNA水平的定量检测、监控及抗病毒药物的筛选、考核。
Objective: To introduce a rapid hybridyzation Quantitative Assay for detecting HBV DNA and to deraonstrate its clini-cal utility. Methods: 79 serum samples from 40 HBsAg positive patients were selected. The HBV DNA of these samples were mea-sured using a hybrid - capture Ⅱ (HC IITM , Digene) and compared with a signal amplification assay based on branched - DNA (bDNA,Bayer). Results: Among 79 serum samples, 57 samples (72.2%)were positive by the HC Ⅱ assay and 45 samples (57%) were positive by the bDNA assay. In comparison with the HCII and bDNA assays, concordant results were found in 73(85.9%)sam-ples, and the results of the two assays were closely comelated (r = 0.95). Of the 19 patients treated with Lamuvidine, the average of HBV DNA Ievels decreased 2(Log10)copies/ml. Among the 6 patients appeared HBeAg seroconversion, the average of HBV DNA Ievels decreased more than 3(Log10)copies/ml, furthermore, The presence of HBV DNA negativity was earlier than HBeAg seroconversion. Condusion: Compared with bDNA, the HC Ⅱ is less complex and less expensive and required a shorter lime(4h) than that of bDNA(24h). It also can be recommended for monitoring HBV DNA Ievels during antivirai therapy.
出处
《中国医药导刊》
2003年第1期25-26,30,共3页
Chinese Journal of Medicinal Guide
